CV risk in HIV patients switching from a boosted PI to DTG

Registry ID

EUCTR2013-003704-39

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

St Stephen's AIDS Trust

Start date

2014-04-01

Completion date

2017-12-04

Last update

2026-08-16

Conditions

• HIV-1 infection
• HIV infection

Summary

To investigate continued virus suppression in individuals switching from a boosted PI containing regimen to a dolutegravir containing regimen after 48 weeks To investigate the change in total cholesterol in individuals switching from a boosted PI containing regimen to a a dolutegravir containing regimen after 48 weeks

Locations

• , , UK
• , , Italy
• , , Belgium
• , , Spain

Related clinical trials

• Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People with HIV-1

View on source registry